ArticleEClinicalMedicine2025
First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brain metastasis: Opportunities for novel therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The primary analysis of the CAP-BRAIN trial has shown preliminary antitumour activity and safety of first-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC) and brain metastases (BMs). Here, we report the final efficacy analysis of the CAP-BRAIN study following an additional 3-years of follow-up from the data cut-off date of the primary analysis, along with updated safety data. Methods: In this multicentre, open-label, single-arm, phase 2 trial conducted at seven hospitals in China, 45 adult patients with treatment-naive metastatic non-squamous NSCLC and asymptomatic BMs (or intracranial hypertension symptom controlled with dehydration therapy) were treated with four cycles of camrelizumab (200 mg) plus pemetrexed (500 mg/m Findings: Between April 13, 2020, and May 12, 2022, 45 (93.8%) of 48 screened patients were enrolled and included in the full analysis set. At data cutoff (May 22, 2025), the median duration of follow-up was 46.7 months (95% confidence interval [CI] 40.7-53.8). The updated confirmed iORR was 57.5% (95% CI 40.9-73.0) in the efficacy analysis set and 51.1% (35.8-66.3) in the full analysis set. The median iPFS was 8.4 months (95% CI 6.2-not reached), and the median overall PFS was 7.2 months (4.5-21.0). The median OS was 18.4 months (95% CI 10.3-29.9). Treatment-related adverse events were reported in 41 (91.1%) of 45 patients. No unexpected safety signals and additional treatment-related deaths were observed. Interpretation: Our final results support the promising benefit and manageable toxicity of first-line camrelizumab plus pemetrexed and carboplatin in non-squamous NSCLC patients with BMs, suggesting the potential for delayed brain radiotherapy in the upfront setting. Further investigation is warranted in a randomised controlled trial. Funding: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.